Health Trials

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

ConditionsMyeloid MalignancyInherited Bone Marrow Failure SyndromeClonal ExpansionCytopeniaBone Marrow Failure SyndromeClonal Cytopenia of Undetermined SignificanceClonal Hematopoiesis of Indeterminate PotentialHematologic NeoplasmsHematopoietic and Lymphatic System NeoplasmHereditary Neoplastic SyndromeIdiopathic Cytopenia of Undetermined SignificanceIdiopathic Dysplasia of Uncertain SignificanceLow Risk Myelodysplastic Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.

Eligibility criteria

Qualifiers

Patients with idiopathic cytopenias of unclear significance (ICUS)

Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential [CHIP]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)

Patients with clonal cytopenias of undetermined significance (CCUS)

Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders

Disqualifiers

Patients under 18 years of age

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Punch Biopsy
  • Buccal Swab
  • Clinical Evaluation
  • Genetic Counseling
  • Quality-of-Life Assessment
  • Electronic Health Record Review

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov